Physician profile
Meiling Wang
NPI 1255038808
$3,931.25
in general payments reported to CMS, 2019-2025
15 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $952 · 2024: $1,374 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,888 · Education: $43.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.08 |
| Education | $43.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,080.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $495.40 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $403.04 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $371.38 | 2024-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $365.16 | 2023-2025 | Trintellix |
| Lundbeck LLC | $331.24 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $201.00 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $134.39 | 2023-2025 | Austedo Xr, Austedo Xr |
| Gilead Sciences, INC. | $116.15 | 2024 | Descovy |
| Vanda Pharmaceuticals INC. | $106.87 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.60 | 2023 | |
| Noven Therapeutics, LLC | $82.17 | 2024-2025 | Xelstrym, Secuado |
| Sumitomo Pharma America, INC. | $69.09 | 2024 | |
| Neurocrine Biosciences, INC. | $39.40 | 2024-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $31.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meiling Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.